Frequently Asked Questions

Get answers to commonly asked questions about the THERA patient support® Program

What is THERA patient support® and how can it help my patients?

THERA patient support® is a personalized patient support program for healthcare providers and patients. The program offers your patients ongoing, personalized support including:

  • Coverage and insurance support
  • Financial assistance resources and information
  • Personalized injection training by one of our experienced THERA patient support® Nurse Navigators

You can find more information on the THERA patient support® program and its service offerings here.

How can THERA patient support® help me and my office staff?

THERA patient support® offers you and your office staff ongoing, personalized support including:

  • Support enrolling patients, including enrollment form assistance
  • Assisting with prior authorization and claim denials/appeals
  • Providing education on payer coverage criteria and policy updates
  • Addressing and solving reimbursement challenges
  • Answering any questions about the THERA patient support® Program

To seamlessly enroll patients online, upload the signed patient consent form and chart notes, track patients’ real-time enrollment status, obtain coverage information, and view the EGRIFTA WRTM shipment information, visit the THERA patient support® Physician Portal.

To access the enrollment form, coverage access forms, and other helpful resources for the THERA patient support® program, visit the THERA patient support® website.

Can patients enroll in THERA patient support® on their own?

Healthcare providers will be required to enroll their patients into the THERA patient support® program.

You can do this in 2 ways:

  • Fax: Download the enrollment form, fill it out, scan it, and fax it to 1-855-836-3069
    OR
  • Online: Prescribe and enroll your patients through the Physician Portal. You will need to register if you do not already have an account.

However, patients will need to provide their consent for enrollment. Patients can provide consent by signing the last page of the enrollment form.

If your patient is unable to sign the back of the enrollment form, they can also provide their consent digitally by:

  • Visiting here OR
  • Calling THERA patient support® at 1‑833‑23THERA (1‑833‑238-4372) and requesting a consent link via SMS

If patient consent is not on file, a THERA patient support® Patient Care Coordinator will reach out to your patient and request consent via SMS.

You can learn more about enrollment and patient consent capture here.

How can I access or learn more about the THERA patient support® physician portal?

You can access the THERA patient support® physician portal here to register and create an account. Once registered, you can use the portal to:

  • Enroll your patients in the THERA patient support® program
  • Track patients’ real-time enrollment status
  • Obtain coverage information
  • Upload chart notes
  • View product shipment information

Does my patient need health insurance to enroll in the THERA patient support® program?

Patients can be enrolled into the THERA patient support® program regardless of insurance status. However, patients will be assessed for eligibility for financial assistance upon enrollment.

The THERA patient support® Financial Assistance Program can help cover the cost of care for eligible EGRIFTA WRTM patients through various support options, including:

  • Commercial Insurance

    The THERA EGRIFTA WRTM Co-Pay Program may help patients with private or commercial insurance lower their out-of-pocket costs.

  • Government Insurance

    THERA patient support® can assist with alternative funding for patients with government insurance that may lower their out-of-pocket costs.

  • Patient Assistance Program

    The THERA Patient Assistance Program offers qualifying patients THERA medications at no cost.

You can find more information on the THERA patient support® program and its service offerings here.

Questions about THERA patient support® services?

Call THERA patient support® program toll free at 1-833-23THERA (1-833-238-4372) and a THERA Patient Care Coordinator will assist you and your office staff. Available Monday to Friday from 8:30 a.m. – 8:00 p.m. EST.

Let’s keep in touch

Enter your contact details to stay up to date with the latest developments from Theratechnologies.

By clicking the “Sign up” button below, I consent to receiving communications from Theratechnologies.

* Mandatory field.

Thank You for Signing Up!

We look forward to keeping you informed with the latest news and updates from Theratechnologies.

IMPORTANT SAFETY INFORMATION ABOUT EGRIFTA WRTM (TESAMORELIN) FOR INJECTION

Indication

EGRIFTA WRTM is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Limitations of Use:

  • The impact and safety of EGRIFTA WRTM on cardiovascular health has not been studied.
  • EGRIFTA WRTM is not indicated for weight loss management.
  • It is not known whether taking EGRIFTA WRTM helps improve compliance with anti-retroviral medications.

Contraindications:

Do not use EGRIFTA WRTM if patient:

  • Has a pituitary gland tumor, has had pituitary gland surgery, has other problems related to their pituitary gland, or has had radiation treatment to their head or a head injury.
  • Has active cancer.
  • Is allergic to tesamorelin or any of the ingredients in EGRIFTA WRTM.
  • Is pregnant or planning to become pregnant.

Warnings and Precautions

  • Increased risk of neoplasms: Preexisting malignancy should be inactive and its treatment complete prior to starting EGRIFTA WRTM. EGRIFTA WRTM should be discontinued if the patient has evidence of recurrent malignancy.
  • Elevated IGF-1: Regularly monitor IGF-1 levels in all patients during EGRIFTA WRTM therapy. Consider discontinuing in patients with persistent elevations (e.g., >3 SDS).
  • Fluid retention: May include edema, arthralgia, and carpal tunnel syndrome.
  • Glucose intolerance or diabetes mellitus: May develop with EGRIFTA WRTM treatment. Evaluate glucose status prior to and during therapy with EGRIFTA WRTM.
  • Hypersensitivity reactions: Advise patients to seek immediate medical attention if suspected.
  • Injection site reactions: Advise patients to rotate sites to different areas of the abdomen to decrease injection site reactions.
  • Increased mortality in patients with acute critical illness: Consider discontinuation in critically ill patients.

Drug Interactions

  • EGRIFTA WRTM had no significant impact on the pharmacokinetic profiles of simvastatin in healthy subjects.
  • Monitor patients for potential interactions when administering EGRIFTA WRTM in combination with other drugs known to be metabolized by CYP450 liver enzyme.
  • Patients on glucocorticoids may require dosage adjustment upon initiation of EGRIFTA WRTM.

Use in Specific Populations

  • Lactation: Mothers should not breastfeed if they receive EGRIFTA WRTM.
  • Pediatric use: Safety and effectiveness in pediatric patients have not been established.
  • Geriatric use: There is no information on the use of EGRIFTA WRTM in patients greater than 65 years of age.

Adverse Reactions

The most commonly reported adverse reactions include injection site reactions, arthralgia, pain in extremity, myalgia, and peripheral edema.

For complete disclosure of EGRIFTA WRTM product information, please read the Full Prescribing Information, Patient Information, and Patient Instructions for Use.

For more information about EGRIFTA WRTM, contact THERA patient support® program toll-free at 1-833-23THERA (1-833-238-4372). To report suspected adverse reactions, contact THERA patient support® program or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.